SynthesisRevista medica del Instituto Mexicano del Seguro Social2024
[Report of 3 cases of acute hemorrhagic leukoencephalitis in Mexico].
Synthesis in Revista medica del Instituto Mexicano del Seguro Social, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute hemorrhagic leukoencephalitis (AHLE) or Weston-Hurst syndrome is a rare and severe variant of acute disseminated encephalomyelitis (ADEM). It causes fulminant hemorrhagic demyelination of the central nervous system, and has high mortality and morbidity. Due to the increase in cases and to its high rate of mortality, we decided to make a series of cases and a review of the disease. Clinical cases: We present 3 cases of Mexican patients, with clinical, radiological, and cerebrospinal fluid presentation compatible with the disease, with little response to treatment and high short-term morbidity. In 2 of the cases, there was positive evidence of aquaporin 4 antibodies (ac-AQP4), without any other apparent trigger. Conclusions: There is little evidence on the clinical evolution and medical management of the disease. With the arrival of the COVID-19 pandemic, there was an increase in cases of these diseases of autoimmune etiology. Although these cases did not present previous infection by COVID 19, there was an increase in the immunogenicity of ab- AQP4. Because of this, we believe it is important to distinguish it, describe as many cases as possible, and provide more information about its diagnosis, treatment, and prognosis. Likewise, we carried out a brief systematic review of the bibliography.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.